Download pdf
The Role of Immune Checkpoint Inhibitors in Renal Cancer: Innovation, Resistance Mechanisms, and Next-generation Strategies
- 1 Institute of Biological Science, The University of Melbourne, Victoria, Australia
* Author to whom correspondence should be addressed.
Abstract
Renal cell carcinoma (RCC) is a prevalent and aggressive malignancy, often diagnosed at advanced stages with limited curative options. The development of immune checkpoint inhibitors (ICIs), especially those that target the PD-1/PD-L1 axis, has significantly transformed the therapeutic landscape of RCC, offering improved survival and disease control. However, a significant percentage of individuals either develop acquired resistance or have primary resistance, limiting the long-term efficacy of ICI-based therapies. This review explores the status of ICI treatment in RCC, summarizing key clinical milestones and response variability. Mechanisms contributing to resistance—such as defective antigen presentation, immunosuppressive tumor microenvironment, and T cell exhaustion —are examined in detail. To address these limitations, combination therapies involving VEGF inhibitors and dual checkpoint blockade (e.g., PD-1/CTLA-4) have demonstrated enhanced antitumor activity in clinical trials. Moreover, the potential of next-generation immune checkpoint targets, such as TIGIT, TIM-3, and LAG-3, to improve immune response is being intensively studied. In parallel, emerging technologies such as artificial intelligence-driven biomarker discovery, personalized neoantigen vaccines, and microbiome modulation are shaping the future of precision immunotherapy in RCC. These innovations aim to identify predictive markers, tailor therapies, and improve patient outcomes. By integrating mechanistic understanding with clinical and technological advancements, a more durable and personalized immunotherapy strategy may be achievable. This review provides a comprehensive overview of ongoing challenges, recent breakthroughs, and future directions for ICIs in RCC, highlighting the need for a multi-pronged approach to overcome resistance and optimize treatment efficacy.
Keywords
renal cell carcinoma, resistance mechanisms, immune checkpoint inhibitors, combination therapy, next-generation immunotherapy
[1]. Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. and Ulbright, T. M. (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. European Urology, 70, 93-105.
[2]. Bahadoram, S., Davoodi, M., Hassanzadeh, S., Bahadoram, M., Barahman, M. and Mafakher, L. (2022) Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. Gastroenterology and Nephrology, 39, 2022.
[3]. Padala, S. A., Barsouk, A., Thandra, K. C., Saginala, K., Mohammed, A., Vakiti, A., Rawla, P. and Barsouk, A. (2020) Epidemiology of renal cell carcinoma. World Journal of Oncology, 11, 79-87.
[4]. Marei, H. E., Hasan, A., Pozzoli, G. and Cenciarelli, C. (2023) Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell International, 23, 64.
[5]. Schoenfeld, A. J. and Hellmann, M. D. (2020) Acquired resistance to immune checkpoint inhibitors. Cancer Cell, 37, 443-455.
[6]. Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y. and Zhang, Y. (2020) T cell dysfunction and exhaustion in cancer. Frontiers in Cell and Developmental Biology, 8, 17.
[7]. Liu, Y. and Cao, X. (2016) Immunosuppressive cells in tumor immune escape and metastasis. Journal of Molecular Medicine, 94, 509-522.
[8]. Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J. and Zhang, B. (2020) Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Frontiers in Immunology, 11, 1956.
[9]. Gu, L., Khadaroo, P. A., Su, H., Kong, L., Chen, L., Wang, X., Li, X., Zhu, H., Zhong, X., Pan, J. and Chen, M. (2019) The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer, 19, 559.
[10]. Lu, C. and Tan, Y. (2024) Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Molecular Therapy Oncology, 32, 200773.
[11]. Joller, N., Anderson, A. C. and Kuchroo, V. K. (2024) LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity, 57, 206-222.
[12]. Shahzadi, M., Rafique, H., Waheed, A., Naz, H., Waheed, A., Zokirova, F. R. and Khan, H. (2024) Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Therapeutic Advances in Vaccines and Immunotherapy, 12, 25151355241305856.
[13]. KHAN, P. A. (2024) Advancing Cancer Care: A Deep Dive into Immunotherapy Strategies.: Immunotherapy Unveiled Exploring Revolutionary Cancer Treatments. Pristyn Research Solutions.
[14]. Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131, 2627-2642.
[15]. Nolla, K., Benjamin, D. J. and Cella, D. (2023) Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. Nature Reviews Urology, 20, 420-433.
[16]. Bagchi, S., Yuan, R. and Engleman, E. G. (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249.
[17]. Ingels, A., Campi, R., Capitanio, U., Amparore, D., Bertolo, R., Carbonara, U., Erdem,S., Kara, Ö., Klatte, T., Kriegmair, M.C., Marchioni, M., Mir, M.C., Ouzaïd, I., Pavan, N., Pecoraro, A., Roussel, E. and de la Taille, A. (2022) Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nature Reviews Urology, 19, 391-418.
[18]. Cai, L., Li, Y., Tan, J., Xu, L. and Li, Y. (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. Journal of Hematology & Oncology, 16, 101.
[19]. Mitra, A., Kumar, A., Amdare, N. P. and Pathak, R. (2024) Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion. Biology, 13, 307.
[20]. Vanmeerbeek, I., Naulaerts, S., Sprooten, J., Laureano, R. S., Govaerts, J., Trotta, R., Pretto, S., Zhao, S., Cafarello, S.T., Verelst,J., Jacquemyn, M., Pociupany, M., Boon, L., Schlenner, S.M., Tejpar, S., Daelemans, D., Mazzone, M. and Garg AD. (2024) Targeting conserved TIM3+ VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy. Science Advances, 10, eadm8660.
Cite this article
Guo,W. (2025). The Role of Immune Checkpoint Inhibitors in Renal Cancer: Innovation, Resistance Mechanisms, and Next-generation Strategies. Theoretical and Natural Science,93,32-38.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).